Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
| Autor: | Egbert F. Smit, Thomas E. Stinchcombe, James R. Jett, David R. Gandara, David R. Spigel, Martin Reck, Fred R. Hirsch, Suresh S. Ramalingam, Ronald B. Natale, Mark A. Socinski, Edward S. Kim, Craig H. Reynolds, Corey J. Langer, Heather A. Wakelee, Jeffrey D. Bradley, Philip Bonomi, Luis Paz-Ares, Silvia Novello, Keith M. Kerr, Maurice Pérol, Nick Thatcher, Coleman K. Obasaju, Johan Vansteenkiste, Paul A. Bunn |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
PD-L1
0301 basic medicine Pulmonary and Respiratory Medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Molecular testing 03 medical and health sciences 0302 clinical medicine Immune system Targeted treatment Internal medicine Biomarkers Tumor Pathology medicine Humans Molecular Targeted Therapy Liquid biopsy Lung cancer Chemotherapy biology business.industry Non–small-cell lung cancer Immunotherapy medicine.disease Radiation therapy Biomarker 030104 developmental biology Immune-oncology 030220 oncology & carcinogenesis Carcinoma Squamous Cell biology.protein business |
| Zdroj: | Hirsch, F R, Kerr, K M, Bunn, P A, Kim, E S, Obasaju, C, Pérol, M, Bonomi, P, Bradley, J D, Gandara, D, Jett, J R, Langer, C J, Natale, R B, Novello, S, Paz-Ares, L, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Stinchcombe, T E, Vansteenkiste, J F, Wakelee, H & Thatcher, N 2018, ' Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer : Effect of Current and Future Therapies and Technologies ', Clinical Lung Cancer, vol. 19, no. 4, pp. 331-339 . https://doi.org/10.1016/j.cllc.2018.03.014, https://doi.org/10.1016/j.cllc.2018.03.014 |
| ISSN: | 1525-7304 |
| DOI: | 10.1016/j.cllc.2018.03.014 |
| Popis: | Patients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non-small-cell lung cancer, with a focus on SqCLC. ispartof: CLINICAL LUNG CANCER vol:19 issue:4 pages:331-339 ispartof: location:United States status: published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect